Before biopharmaceutical companies raise money from venture capital firms, their early funding often comes from the U.S. government in the form National Institutes of Health grants. That was the case ...
Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse ...
Recursion RXRX is slated to report first-quarter 2024 results on May 9, after market close. The Zacks Consensus Estimate is pegged at a loss of 43 cents per share. The Zacks Consensus Estimate for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback